Overview

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Treatments:
Bevacizumab
Nivolumab